Kurata, Takayasu

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 6,607

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 5,508

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 2,914

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,798

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 733

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 244

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 115

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

Miura, S., Tanaka, H., Misumi, T., Yoshioka, H., Tokito, T., Fukuhara, T., Sato, Y., Shiraishi, Y., Naoki, K., Akamatsu, H., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 37

Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions

Dohi, T., Miyauchi, K., Okazaki, S., Yokoyama, T., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., & Daida, H. (2011) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesCoronary Interventions and Diagnostics

Cited by 26